Insights - Magenta presented data for their mobilizing agent MGTA-145 at the European Society for Blood and Marrow Transplantation (EBMT 2021). The data was not new, but it gave … Continue Reading
PremiumInsights - Biotech (XBI) had a rough week as investors are moving away from “risky” assets due to the expected rise in interest rates. The XBI ETF, … Continue Reading
PremiumInsights - We wrote about Magenta (MGTA) back in the summer of 2020 when the stock was in the $9 range. The thesis was that MGTA was … Continue Reading
PremiumInsights - We think there are some solid value plays with the current market rout. We’re looking at companies with enough cash to weather the storm and … Continue Reading
PremiumInsights - Adverum released preliminary Phase 1 data prior to the market opening. Data was rather vague and did not meet our expectations because it did not clearly place … Continue Reading
PremiumInsights - ADVM will present Phase 1 data in Wet AMD this September We set expectations for September data by looking at competitor RGNX Phase 1 data … Continue Reading
PremiumInterviews - Operator: Thank you for holding. Welcome to the Selecta Biosciences fourth quarter and year end 2017 conference call. Currently all participants are in a listen … Continue Reading
Read now
